TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8612412

Group type: EXPERIMENTAL
Intervention: Propofol (0.75 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propofol (0.35 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1329937

Group type: EXPERIMENTAL
Intervention: Variable oestrogen dosage regimen
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fixed 1 mg oestrogen dosage regimen
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fixed 2 mg oestrogen dosage regimen
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fixed 4 mg oestrogen dosage regimen
Number of subjects: 21
Study: 6574611

Group type: EXPERIMENTAL
Intervention: Fortnightly sodium fluoride rinsing and topical painting with ferric aluminum fluoride solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fortnightly sodium fluoride rinsing and topical painting with neutral 0.2% sodium fluoride solution
Number of subjects: 0
Study: 29143462

Group type: EXPERIMENTAL
Intervention: ABG/melatonin composite graft
Number of subjects: 26

Group type: COMPARATOR
Intervention: ABG (control group)
Number of subjects: 26
Study: 28826168

Group type: EXPERIMENTAL
Intervention: Functional resistance training (12-week period, 24 sessions, 2 days per week)
Number of subjects: 19
Study: 27922448

Group type: EXPERIMENTAL
Intervention: Telephone-facilitated cCBT
Number of subjects: 369

Group type: COMPARATOR
Intervention: Minimally supported cCBT
Number of subjects: 369
Study: 24270198

Group type: EXPERIMENTAL
Intervention: Conservative management by cytology every 6 months in primary care
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Presence of HPV-18
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Presence of HPV-16 and/or HPV-18 at recruitment
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combined HPV-16/HPV-18 test
Number of subjects: 171
Study: 19249429

Group type: EXPERIMENTAL
Intervention: clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: prasugrel 60 mg LD/10 mg MD
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 110
Study: 15097437

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3 g/kg/day for 7 days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 11556508

Group type: EXPERIMENTAL
Intervention: Iodine potassium iodide (IKI) irrigation for 5 min after cleaning and shaping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium hydroxide filling for 10-14 days after cleaning and shaping
Number of subjects: 40
Study: 9489975

Group type: EXPERIMENTAL
Intervention: Urokinase (192 U/ml, 1920 U/ml, 19,200 U/ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (120 U/ml, 1200 U/ml, 12,000 U/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (160 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (660 mg/day)
Number of subjects: 12
Study: 7838915

Group type: EXPERIMENTAL
Intervention: d-amphetamine (15 mg) with vigilance activity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: triazolam (0.25 mg) with relaxation activity
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo with vigilance activity
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo with relaxation activity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine (15 mg) with relaxation activity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: triazolam (0.25 mg) with vigilance activity
Number of subjects: 8
Study: 3169214

Group type: EXPERIMENTAL
Intervention: Budesonide (high dose, 1,000 and 1,200 micrograms per day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Beclomethasone (high dose, 1,000 and 1,200 micrograms per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Beclomethasone (800 micrograms per day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Beclomethasone
Number of subjects: 31
Study: 12207833

Group type: EXPERIMENTAL
Intervention: Spinach meals with a mono:polyglutamate ratio 40:60
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spinach meals
Number of subjects: 11

Group type: COMPARATOR
Intervention: Folic acid supplement
Number of subjects: 11
Study: 30762945

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (median dose after 50 min 0.09 (range 0-0.26) μg kg-1 min-1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (standard care, NA administered only if MAP decreased below 60 mmHg)
Number of subjects: 24
Study: 30340488

Group type: EXPERIMENTAL
Intervention: QUEST tool
Number of subjects: 45

Group type: COMPARATOR
Intervention: Existing tools
Number of subjects: 45
Study: 27806634

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 52
Study: 24872552

Group type: EXPERIMENTAL
Intervention: Global similarity among activation patterns in the medial temporal lobes (MTLs)
Number of subjects: 0
Study: 23122534

Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study: 20040526

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks, followed by 125 mg twice daily for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 17
Study: 18807726

Group type: EXPERIMENTAL
Intervention: Evening‐EA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morning‐EA
Number of subjects: 60
Study: 16005336

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Minimal Acupuncture
Number of subjects: 294

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting List
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Minimal Acupuncture after 52 weeks
Number of subjects: 294
Study: 11901542

Group type: EXPERIMENTAL
Intervention: Peptide vaccines derived from tumor antigens
Number of subjects: 0
Study: 10352750

Group type: EXPERIMENTAL
Intervention: Octreotide treatment (daily dosage of 470 +/- 160 micrograms for 16.5 +/- 10 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no Octreotide treatment)
Number of subjects: 24
Study: 8619354

Group type: EXPERIMENTAL
Intervention: Iobitridol 300 mg I/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Iopromide 300 mg I/ml
Number of subjects: 60
Study: 1953212

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily at bedtime (n = 15)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Probucol 500 mg twice daily (n = 11)
Number of subjects: 26
Study: 7171967

Group type: EXPERIMENTAL
Intervention: Simple mastectomy and postoperative radiotherapy (for clinical stage I)
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Simple mastectomy and postoperative radiotherapy (for clinical stage II)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Radical mastectomy (for clinical stage II)
Number of subjects: 1022
Study: 31142272

Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: In-Person
Number of subjects: 78
Study: 30186865

Group type: EXPERIMENTAL
Intervention: Ultrasonic implant site preparation (UISP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional rotary instrumentation (control)
Number of subjects: 48
Study: 27278250

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for psychotic disorders (18 months of therapy including 60 hours of group therapy and 15 hours of individual therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 24488700

Group type: EXPERIMENTAL
Intervention: SSRIs treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Combination of neuroendocrine factors
Number of subjects: 290
Study: 22142278

Group type: EXPERIMENTAL
Intervention: Planning (Week 5)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Younger individuals with stronger intention and higher maintenance self-efficacy
Number of subjects: 571
Study: 19453582

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + ketamine 0.5 mg.kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + same volume of %0.9 NaCl
Number of subjects: 60
Study: 17444593

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adalimumab (after Week 12)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (after Week 12)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adalimumab and placebo
Number of subjects: 100
Study: 15265969

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (four cycles of doxorubicin 75 mg/m2, followed by a single cycle of intermediate-dose cyclophosphamide 4000 mg/m2 supported by filgrastim 300 microg/day for up to 10 days, followed by high-dose cyclophosphamide 6000 mg/m2 and thiotepa 800 mg/m2)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Conventional chemotherapy (four cycles of doxorubicin 75 mg/m2 followed by eight cycles of CMF: cyclophosphamide 600 mg/m2, methotrexate 50 mg/m2, and 5-fluorouracil 600 mg/m2)
Number of subjects: 605
Study: 12398998

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil (5-FU) and folinic acid (LV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and folinic acid (LV)
Number of subjects: 0
Study: 9534093

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7663253

Group type: EXPERIMENTAL
Intervention: Intervention group (n=6489) taught to order radiography according to the Ottawa ankle rules
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Control group (n=6288)
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Community hospitals intervention group
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Community hospitals control group
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Teaching hospitals intervention group
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Teaching hospitals control group
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Emergency physicians intervention group
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Emergency physicians control group
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Family physicians intervention group
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Family physicians control group
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Housestaff intervention group
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Housestaff control group
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Intervention group (no radiography)
Number of subjects: 12777

Group type: COMPARATOR
Intervention: Control group (with radiography)
Number of subjects: 12777

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 12777
Study: 2486586

Group type: EXPERIMENTAL
Intervention: Thoracic epidural catheter placement within 72 hours from the time of admission to the ICU (Group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard morphine parenteral analgesia (Group 1)
Number of subjects: 28
Study: 1086422

Group type: EXPERIMENTAL
Intervention: Intramuscularly applied leucovorin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Leucovorin-tablets
Number of subjects: 45
Study: 30526692

Group type: EXPERIMENTAL
Intervention: 10 µg vitamin D3/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 35 µg vitamin D3/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: >85 µg vitamin D3/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 60 µg vitamin D3/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 85 µg vitamin D3/d
Number of subjects: 43
Study: 28601750

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25075773

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of three 5-minute cycles of forearm ischemia followed by reperfusion
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care without RIPC
Number of subjects: 86
Study: 23848107

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (10 mg/day for 6 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study: 21050679

Group type: EXPERIMENTAL
Intervention: CBT4CBT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 52
Study: 18993044

Group type: EXPERIMENTAL
Intervention: Ventilator with automated air-leak compensation system
Number of subjects: 14
Study: 17471343

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 198
Study: 12775929

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal sitting (without CPM device)
Number of subjects: 0
Study: 10855680

Group type: EXPERIMENTAL
Intervention: 15% carbohydrate‐electrolyte drink (1.45+/‐0.29 litres)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2% carbohydrate‐electrolyte drink (3.12+/‐0.47 litres)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No drink
Number of subjects: 6
Study: 9401795

Group type: EXPERIMENTAL
Intervention: Neurofibrillary tangles counted via light microscopy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Neurofibrillary tangles in the very anterior part of the entorhinal cortex
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Neurofibrillary tangles in the anterior part of the right entorhinal region
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: No neurofibrillary changes visible
Number of subjects: 9
Study: 8498867

Group type: EXPERIMENTAL
Intervention: Surgical treatment of varicocele (26 patients)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sclerosation or embolization (12 patients)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No therapy (41 patients)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All treatments (surgical, sclerosation, embolization)
Number of subjects: 96
Study: 2423826

Group type: EXPERIMENTAL
Intervention: Amniocentesis
Number of subjects: 4606

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 4606
Study: 31273791

Group type: EXPERIMENTAL
Intervention: Dengue virus serotype 2 (DENV2) identified through polymerase chain reaction and Sanger's sequencing
Number of subjects: 24807

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of DENV2 isolates
Number of subjects: 24807
Study: 29049235

Group type: EXPERIMENTAL
Intervention: Fold-type respirator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cup-type respirator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Valve-type respirator
Number of subjects: 30
Study: 27250601

Group type: EXPERIMENTAL
Intervention: 4 l polyethylene glycol (PEG) in a single dose
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: 4 l polyethylene glycol (PEG) split into 3 + 1 l
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: PEG + ascorbic acid (PEGA) split into 1 + 1 l or 2 l
Number of subjects: 380

Group type: COMPARATOR
Intervention: PEG and PEGA in similar regimens
Number of subjects: 380
Study: 23799553

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 61
Study: 22400970

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 276
Study: 19322744

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/day (n=23)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo (n=17)
Number of subjects: 40
Study: 17911549

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid artery angioplasty and stenting (CAS)
Number of subjects: 0
Study: 12620950

Group type: EXPERIMENTAL
Intervention: Continuous intra‐articular infusion with 0.2% ropivacaine at 10 mL/hr for 48 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Continuous interscalene block with 0.2% ropivacaine at 10 mL/hr for 48 hours
Number of subjects: 17
Study: 10946875

Group type: EXPERIMENTAL
Intervention: High serum levels of insulin-like growth factor I (IGF-I)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor binding protein-3 (IGFBP-3)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Prostate volume
Number of subjects: 665
Study: 8817135

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg every 6 hours postoperatively)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg per hour i.v.)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study: 1486965

Group type: EXPERIMENTAL
Intervention: Salmeterol (SML; 50 micrograms b.i.d.)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Slow-release theophylline and ketotifen (TK; T 300 mg+K 1 mg b.i.d.)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Salmeterol (SML)
Number of subjects: 96
Study: 6363488

Group type: EXPERIMENTAL
Intervention: Atropine 0.26 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine 2.08 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3764397

Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg i.m.)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Hydrocodonum (15 mg i.m.)
Number of subjects: 122
Study: 30170854

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 758
Study: 28644114

Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 25780074

Group type: EXPERIMENTAL
Intervention: CPAP by helmet
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPAP by mask
Number of subjects: 30
Study: 23706700

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Fluorescein angiography (FA)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Biomicroscopy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Agreement between OCT and FA
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Macular leakage (ML) presence
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Macular thickening (MT) presence
Number of subjects: 255

Group type: COMPARATOR
Intervention: Biomicroscopic evaluation
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Phakic eyes without cataract
Number of subjects: 255
Study: 20939644

Group type: EXPERIMENTAL
Intervention: Alcohol dose of .100%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Alcohol dose of .075%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Alcohol dose of .050%
Number of subjects: 185

Group type: COMPARATOR
Intervention: Alcohol dose of .000%
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: GoStop Impulsivity Paradigm
Number of subjects: 185
Study: 18250972

Group type: EXPERIMENTAL
Intervention: C1‐INH activity ≤ 10%
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: C1‐INH activity 10‐52%
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Contact with H. pylori
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Anti-HBc positive patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HBV DNA testing
Number of subjects: 65

Group type: COMPARATOR
Intervention: MBL concentration and MBL/MASP‐2 complex activity
Number of subjects: 65
Study: 16790517

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² on day 1 and gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks (group A)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Paclitaxel and pegylated liposomal doxorubicin 40 mg/m² on day 1 every 4 weeks (group B)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 166
Study: 15035763

Group type: EXPERIMENTAL
Intervention: Albuterol by nebulizer every 20 minutes up to 2 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler with spacer every 20 minutes up to 2 hours
Number of subjects: 50
Study: 11099870

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) and oral medroxyprogesterone acetate
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oral cyclic association of oestradiol valerate and cyproterone acetate
Number of subjects: 240
Study: 9214139

Group type: EXPERIMENTAL
Intervention: Miprovit
Number of subjects: 90
Study: 1606067

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, adriamycin, and cisplatin (CAP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cyclophosphamide, adriamycin, and vincristin (CAV)
Number of subjects: 83
Study: 3885202

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 30099933

Group type: EXPERIMENTAL
Intervention: NIT-RW (polyphenol-rich red wine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NIT-A (low polyphenol alcoholic beverage - vodka)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NIT-CON (water)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (low NO3- salad and water)
Number of subjects: 12
Study: 27037435

Group type: EXPERIMENTAL
Intervention: Exsanguination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Elevation
Number of subjects: 26
Study: 24636526

Group type: EXPERIMENTAL
Intervention: Pomalidomide with or without corticosteroids
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 85